Thorsten Waloschek/LinkedIn
Dec 21, 2025, 02:24
Thorsten Waloschek: New Study Highlights Preeclampsia Risk Stratification Benefits
Thorsten Waloschek, CEO of NeoPredics AG, shared a post on LinkedIn:
“This is an important signal for maternal health innovation in pregnancy.
A large new study shows that identifying women at higher risk of preeclampsia late in pregnancy, and acting on that risk with planned early-term birth, reduced term preeclampsia by around 30%.
Risk stratification, biomarkers, and structured decision-making during pregnancy can change outcomes – even without new drugs. This reinforces how much potential still sits in smarter diagnostics and data-driven pathways to protect mothers’ cardiovascular health during pregnancy.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 16, 2026, 01:10Christopher Robinson: Immune Tolerance Breakdown in Pregnancy
-
Apr 16, 2026, 01:06Standardizing Ultrasound Assessment of Adnexal Tumors – ISUOG
-
Apr 15, 2026, 16:38Why an Ovulation Trigger Shot Sometimes Fails – Fertility Plus
-
Apr 15, 2026, 16:3374 New Studies Added to the AC Forum Literature Library – Anticoagulation Forum
-
Apr 15, 2026, 16:23Insights from PGT-A in Recurrent IVF Failure – Motherhood Training Center
-
Apr 15, 2026, 16:20Effect of Endometriosis and Adenomyosis on Oocyte Quality and Morphology – RBMO
-
Apr 15, 2026, 11:37Ally Murji: Honoured to be Part of the Canadian Session at the SEUD Meeting
-
Apr 15, 2026, 11:00Scammers are Targeting ESHRE2026 Attendees With Fake Registration and Hotel Offers – ESHRE
-
Apr 15, 2026, 10:24Join Us This Friday for Our “Research in Progress” – SRF